secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001728117-22-000099
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q3 2022 net loss $59.4M; cash $304.4M; TORREY topline expected Nov/Dec
--------------------------------------------------------------------------------

- Net loss $59.4M ($0.65/shr) vs $60.2M ($0.80/shr) in Q3 2021; cash $304.4M sufficient into Q2 2024.
- R&D expenses $44.5M, G&A $11.5M for quarter ended Sep 30, 2022.
- Phase 2 TORREY topline data for seralutinib expected in second half of Nov or first half of Dec 2022.
- Enrollment ongoing in Phase 1b/2 STAR CNS study of GB5121 for relapsed/refractory CNS lymphomas.
- Preclinical pipeline updates presented at multiple medical conferences; three internally developed programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000099/0001728117-22-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000099/goss-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001728117-22-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer